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Pigment epithelium-derived factor (PEDF) was ﬁrst identiﬁed in retinal pigment epithelium cells. It is an endogenously produced
protein that is widely expressed throughout the human body such as in the eyes, liver, heart, and adipose tissue; it exhibits
multiple and varied biological activities. PEDF is a multifunctional protein with antiangiogenic, antitumorigenic, antioxidant,
anti-inﬂammatory,antithrombotic, neurotrophic, and neuroprotective properties. More recently, PEDF has been shown to be the
most potent inhibitor of stem/progenitor cell-associated neovascularization.Neovascularization is a complex process regulated by
a large, interacting network of molecules from stem/progenitor cells. PEDF is also involved in the pathogenesis of angiogenic
eye disease, tumor growth, and cardiovascular disease. Novel antiangiogenic agents with tolerable side eﬀects are desired for
the treatment of patients with various diseases. Here, we review the value of PEDF as an important endogenous antiangiogenic
molecule; we focus on the recently identiﬁed role of PEDF as a possible new target molecule to inﬂuence stem/progenitor cell-
related neovascularization.
1.Introduction
In the 1980s, pigment epithelium-derived factor (PEDF)was
identiﬁed and isolated from primary human fetal retinal pig-
ment epithelial cells [1]. It is a 50kDa secreted glycoprotein
thatisa noninhibitory memberofthe serpin (serine protease
inhibitor) superfamily of proteins; its gene (SERPINF1)i s
locatedonchromosome 17p13[2].PEDFisanendogenously
produced protein widely expressed throughout the human
body such as in the eye, liver, heart, and adipose tissue,
which exhibitsmultipleandvaried biologicalactivities[3,4].
PEDF was initially identiﬁed as a neurotrophic factor that
diﬀerentiates retinoblastoma cells into nonproliferating neu-
rons [5].PEDFhasalsobeenshowntobeneuroprotectivefor
motor neurons [6], hippocampal neurons [7], dopaminergic
midbrain neurons [8], and striatal neurons [9]i nd i ﬀerent
toxin-induced models of neurodegeneration. These eﬀects
are parallel to the eﬀects of PEDF on neurogenesis in
the context of the neurovasculature. Thereafter, it was
further discovered that PEDF also had potent antiangiogenic
activity, greater than any other known endogenous factor
[10, 11]. The implications of this discovery have proven to
be extensive, and many studies have investigated the role of
PEDF in various pathological conditions, including chronic2 Journal of Biomedicine and Biotechnology
inﬂammatory disease [12], cardiovascular disease [13, 14],
angiogenic eye disease [15], diabetic complications [16], and
cancer [17–20].
Although most research has been done in ocular neovas-
cularandneurodegenerativediseases, overthepastfew years,
PEDF has been described as a multifaceted protein with
antiangiogenic, antiatherosclerosis, antitumorigenic, antiox-
idant,anti-inﬂammatory, antithrombotic,neurotrophic,and
neuroprotective properties (Figure 1)[ 4]. Neovasculariza-
tion is a complex process regulated by a large interacting
network of molecules from stem/progenitor cells [21–24].
More recently, PEDF has been shown to be the most potent
inhibitor of stem/progenitor cell-mediated neovasculariza-
tion [25]. Novel antiangiogenic agents with tolerable side
eﬀects are desired for the treatment of patients with various
diseases [20, 26]. Here, we review the value of PEDF as an
important endogenous antiangiogenic molecule; we focus
on the recently identiﬁed role of PEDF as a possible new
target molecule to inﬂuence stem/progenitor cell-related
neovascularization therapeutically.
2.Stem/ProgenitorCellsand
Neovascularization
Angiogenesis and vasculogenesis are the major types of
postnatal neovascularization. Angiogenesis is the process
where new vessels grow from preexisting blood vessels;
whereas vasculogenesis is the process of blood vessel for-
mation occurring by de novo production of bone marrow
(BM) stem/progenitor cell-derived endothelial cells (ECs),
which, in turn, form blood capillaries (Figure 2)[ 27].
Neovascularization is an important process in the functional
recovery of pathological conditions, such as wound healing
and ischemic diseases. Hypoxia is an important driving
force for neovascularization in various ischemic conditions
through stimulation of the expression of many cytokines
and growth factors such as vascular endothelial growth
factor (VEGF), platelet-derived growth factor, insulin-like
growth factor, and ﬁbroblast growth factor (FGF), which
play critical roles in induction of neovascularization [28].
Other cellular components including monocytes, T cells,
neutrophils, and platelets play signiﬁcant roles in the
induction and modulation of neovascularization. Various
stem/progenitor cells are also recruited to the ischemic
sites and play crucial roles in neovascularization [29].
Preclinical studies have shown that stem/progenitor cells
with or without a combination of growth factors induce
neovascularization in ischemic tissues in various animal
models [30, 31].
Following ischemia, various angiogenic factors and
cytokines are upregulated and promote homing of stem/
progenitor cells to the site of injury [32]. It has been shown
that circulating stem/progenitor cells could be incorporated
into the neovasculature within the ischemic tissue and could
diﬀerentiate into ECs [33, 34]. Stem/progenitor cells can
also diﬀerentiate into other supporting cells, which deliver
growth factors and cytokines to ischemic tissue and promote
angiogenesis through paracrine eﬀects [35]. These cells
primarily include various leukocytes as well as ﬁbroblasts
and pericytes [36–38]. Stem/progenitor cells in peripheral
blood have been shown to diﬀerentiate into both early
endothelial progenitor cells (EPCs), which function through
paracrine eﬀects, and late EPCs, which function directly
through vasculogenesis [39, 40].
InthecontextofEPCbiology,vasculogenesisincludesthe
de novo formation of vessels via in situ migration, prolifer-
ation, diﬀerentiation, and/or incorporation of BM-derived
EPCs into the regenerating vasculature [41]. BM-derived
EPCs can localize to vascular structures during skeletal
and cardiac ischemia [41, 42], wound healing [43], tumor
growth [44], and corneal neovascularization [45]. EPCs also
produce a variety of proangiogenic cytokines and growth
factors,promotingproliferationandmigrationofpreexisting
ECs, activation of angiogenesis, and contributing to vascular
regeneration and the reestablishment of tissue homeostasis
[46]. Therefore, EPCs function via activation and support of
vasculogenesis and may also be major players involved in the
activation and mediation of angiogenesis [21], the process of
new vessel formation, via in situ proliferation and migration
ofpreexistingECs[47].This paracrineaspectofEPCactivity,
reﬂecting itsindirect contributiontoneovascularization, was
conﬁrmed by several reports demonstrating the presence of
various cytokines and other secreting proangiogenic factors
in EPCs [48, 49].
3.OcularBiology
Most diseases cause blindness due to neovascularization.
Neovascularization is a complex process regulated in adult
tissues by a large interacting network of molecules. Hem-
orrhaging vessels cause edema and damage to surrounding
tissues, particularly the retina. Microvascular lesions often
cause severe retinal detachment and loss of vision [15].
PEDF was shown to prevent retinal cell death and counter
t h ea b n o r m a lv e s s e lg r o w t hi n d u c e db yV E G Fi nt h ee y e .
Therefore, PEDF has been shown to be the most potent
inhibitor of angiogenesis in the mammalian eye and is
involved in the pathogenesis of angiogenic eye disease such
as proliferative diabetic retinopathy.
The retina is subject to degenerative conditions leading
to blindness. Although retinal regeneration is possible in
lower vertebrates, it does not occur in the adult mammalian
retina. Arnhold et al. [50] determined the potential of ade-
novirally transduced bone marrow stromal cells (BMSCs) to
diﬀerentiateinto retinal-pigment-epithelial- (RPE-)likecells
and evaluated possible rescue eﬀects after transplantation
into the retinas of rats [51, 52]. Through an adenoviral
vector expressing PEDF, BMSCs were transduced before
subretinal transplantation into rats. They showed, for the
ﬁrst time, that BMSCs have the ability to adopt an RPE-like
morphology after subretinal grafting into rats. Furthermore,
BMSCs were able to induce signiﬁcant rescue eﬀects for the
preservationofphotoreceptorcellnuclei.Theserescueeﬀects
could be increased in dystrophic rats with an adenoviral
vector carrying the PEDF gene. Their ﬁndings indicate a
possible therapeutic option of PEDF for the treatment ofJournal of Biomedicine and Biotechnology 3
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Figure 1: The medicinal properties (antiangiogenic, antiatherosclerosis, antitumorigenic, antioxidant, anti-inﬂammatory, antithrombotic,
neurotrophic, and neuroprotective properties) of PEDF.
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Figure 2: Schematicrepresentation ofpostnatalneovascularization
(angiogenesis and vasculogenesis).
photoreceptor cells and visual loss originally caused by
degeneration of the RPE layer [50].
Choroidal neovascularization is a common cause of
severe and irreversible visual loss; however, the treatment
of choroidal neovascularization has been hindered by its
complex and poorly understood pathogenesis [53]. BM-
derived cells are postulated to contribute to choroidal
neovascularization [54], but little is known about their ther-
apeutic potential for the treatment. Hou et al. reported that
BM-derivedmesenchymal stemcells(MSCs)transplanted by
intravenous injection into a laser-induced mouse model of
choroidal neovascularization were speciﬁcally recruited into
the lesions, where they diﬀerentiated into multiple cell types
and participated in the process of neovascularization. Engi-
neered MSCs with PEDF at the choroidal neovascularization
site inhibited the growth of choroidal neovascularization
and stimulated regressive features. Their results suggest
that MSCs contribute to choroidal neovascularization and
could serve as delivery vehicles of antiangiogenic PEDF for
the treatment of a range of choroidal neovascularization-
associated eye diseases [55].
R e t i n a ls t e mc e l l( R S C )r e s e a r c ha l s oo ﬀers unique
opportunitiesfordevelopingapplicationsforretinal regener-
ation therapy. The ciliary body of adult mammals represents
a source of quiescent RSCs. These neural progenitors have
limited self-renewal potential in vitro, but this potential can
be improved by mitogens. De Marzo et al. tested combi-
nations of PEDF with FGF during RSC growth to evaluate
self-renewal and subsequent diﬀerentiation into retinal-like
neuronal cell types. It was shown that PEDF might be a
modulator during cell division promoting the generation
of stem/progenitor cells. Thus, PEDF may contribute to
the amelioration of RSC expansion, oﬀering a source of
alternative therapy in regenerative medicine (Figure 3)[ 56,
57].
Human embryonic stem-cell-derived RPE transplanta-
tion is a promising therapy for atrophic age-related mac-
ular degeneration (AMD). However, future therapeutic
approaches might entail cotransplantation of embryonic
stem-cell-derived RPE with retinal progenitor cells (RPCs)
as a replacement source for lost photoreceptors. Zhu et al.
determined the eﬀect of polarization of embryonic stem-
cell-derived RPE monolayers on their ability to promote
survivalofRPCs.Theyfoundpolarizedembryonicstem-cell-
derivedRPEcellssecretehighlevelsofPEDFthatcansupport
RPC survival suggesting that polarization of embryonic
stem-cell-derived RPE would be an important feature for
the promotion of RPC survival in future cell therapy for
atrophic AMD [58]. In addition, Vaajasaari et al. reported
the diﬀerentiation of functional RPE-like cells from several
stem cell lines in culture conditions. The diﬀerentiated cells
were able to secrete PEDF characteristic of native RPE cells.
Their results showed that RPE-like cells can be diﬀerentiated
in xeno-free, deﬁned cultureconditions, which is mandatory4 Journal of Biomedicine and Biotechnology
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Figure 3:Schematicrepresentationofchoroidalneovascularization.PEDFwasshownto preventretinalcell deathandcountertheabnormal
v e s s e lg r o w t hi n d u c e db yV E G Fi nt h ee y e .
forgoodmanufacturing practiceproductionofthesecellsfor
clinical use [59].
Proliferative diabetic retinopathy is characterized by
pathological retinal neovascularization. PEDF contains an
N-terminal 34-amino acid peptide (PEDF-34). Longeras et
al. presented data that PEDF-34 also possesses antivasculo-
genic activity; PEDF-34 attenuates EPC mobilization from
the BM into circulating blood during retinal neovascular-
ization [25]. Since PEDF controls the neuroprotective and
antineovascular regulatory axis that determines cell growth,
it could be used in combination therapeutic strategies for
ocular neovascular diseases [60].
4.CancerBiology
Cancer remains a major medical problem associated with
considerable morbidity and mortality [61]. It is important
for researchers to improve the current therapeutic agents for
cancer treatment, particularly targeting inhibition of tumor
growth, survival, and metastasis. Cancer stem cells (CSCs),
a special subpopulation of tumor cells, are considered to be
tumor-initiating cells. More recently, these cells have also
been identiﬁed as initiators of tumor neovascularization
[62]. Vasculogenic mimicry—a newly deﬁned pattern of
tumorbloodsupply—providesaspecialpassage withoutECs
and is conspicuously diﬀerent from neovascularization. The
biological features of the tumor cells that form vasculogenic
mimicry remain unclear. CSCs are believed to be tumor-
initiating cells, capable of self-renewal and multipotent
diﬀerentiation, which resemble normal stem cells in phe-
notype and function. CSCs have recently been shown to
contribute to vasculogenic mimicry formation as well as
angiogenesis. The importance of vasculogenic mimicry in
tumor progression suggests that it could constitute a novel
therapeutic target for cancer [63].
Many researchers are investigating the crucial role of
the proangiogenic factor VEGF in tumor angiogenesis,
where the formation of new blood vessels carrying essential
nutrients to the tumor cell becomes a critical factor for
tumor growth [64]. Since VEGF plays an integral role
in mediating tumor angiogenesis and tumor cell survival,
currenteﬀortsarededicatedtodevelopingtherapeuticagents
against VEGF; one emerging candidate is PEDF [65]. PEDF
has recently shown promise as a potential antitumor agent,
causing both direct and indirect tumor suppression. Here,
we brieﬂy introduce the unique antitumor properties of
PEDF and discuss its role as an eﬀective antiangiogenic,
antiproliferative, and prodiﬀerentiation factor (Figure 4).
Thepooroutcomeofcancergenetherapyinclinicaltrials
relates, in part, to insuﬃcient gene delivery to tumor sites.
MSCs represent a new tool for the delivery of therapeutic
agents to tumor cells [66, 67]. Fitzgerald et al. used tumor
cells overexpressing PEDF to establish PEDF as both a
metastatic suppressor and a neuroprotectant in the brain in
vivo[68].Gaoetal.usedanudemicemodelofhepatocellularJournal of Biomedicine and Biotechnology 5
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Figure 4: Schematic representation ofCSC participation in vasculogenicmimicry and neovascularizationinitiated by the presence of EPCs.
Likeintumorangiogenicsprouting,neovascularizationstartswiththesecretionofproangiogenicfactors(suchasVEGF) bythetumorunder
hypoxia. The proangiogenic factors circulate into the bloodstream towards the bone marrow, targeting the release of EPCs. The activated
EPCs form a column from the existing blood vessel. PEDF has antitumor properties as an eﬀective antiangiogenic, antiproliferative, and
prodiﬀerentiation factor.
carcinoma (HCC) to evaluate the potential of genetically
modiﬁed human MSCs to function as an eﬀective delivery
vehicle for therapeutic genes. MSCs derived from the BM
were eﬃciently engineered to express human PEDF by
lentiviral transduction and then tested in vitro for high-level
expression and bioactivity of the transgenic protein. The
preferential homing of MSCs toward HCCs was conﬁrmed
by in vitro and in vivo migration assays. In vivo eﬃcacy
experiments showed that intravenous injection of PEDF-
expressing MSCs signiﬁcantly suppressed both the growth
of primary liver tumors and the development of pulmonary
metastases. Moreover, MSC-based PEDF gene delivery mod-
erately increased systemic levels of human PEDF. Immuno-
histochemistry of primary liver tumors demonstrated lower
microvessel density in mice treated with MSC-PEDF than
in control mice. This study shows, for the ﬁrst time, the
tropism of MSCs derived from the BM for HCC. MSCs
can be genetically modiﬁed ex vivo to express the PEDF
gene that has therapeutic eﬃcacy against HCC. Their results
suggest a potential role of MSCs as a targeted, therapeutic
delivery vehicle for the treatment of HCC. Although this
study indicatesthat PEDFis a good therapeuticagentworthy
of assessment in HCC, the same approach might also be
exploitedinthe treatment ofpatientswith othertumortypes
[69]. A better understanding of the contribution of PEDF
and CSCs to neovascularization should elucidate the mecha-
nisms of cancer initiation and progression as well as establish
new concepts for cancer diagnosis and treatment [70, 71].
5.Cardiovascularand NeurovascularBiology
Cardiovascular and neurovascular diseases are worldwide
causes of morbidity and mortality [72–76]. Stem cells and
EPCs have been studied as novel and promising strategies
for the treatment of these vascular-associated diseases [35].
Adult peripheral blood contains BM-derived EPCs with
propertiesandmarkersthataresimilartoembryonic-derived
angioblasts[77].Recentstudieshaveshown thatBM-derived
stem/progenitorcells canrepair the endothelium,in contrast
to the traditional concept that postnatal tissue revascular-
ization was achieved by neighboring endothelial replication
[78]. The progressive impairment of endothelial function
and integrity starts a cascade of events leading to microcir-
culation damage [79], atherosclerosis, and common cardio-
vascular and neurovascular diseases such as coronary heart
disease (CHD), myocardial infarction (MI), heart failure
(HF),peripheralarterial disease(PAD),dementia,andstroke
[80].TheproliferationrateofECsisverylowinadults,which
limits the contribution of ECs to neovascularization. EPCs
promote vascular repair and provide the rationale for autol-
ogous stem cell therapy [81]. Recently, EPCs have been vig-
orously investigated in various ﬁelds of medicine. Changes
in EPC number have also been investigated in diseases
other than cardiovascular and neurovascular diseases, such
as metabolic disorders, neoplastic pathologies, rheumatic
disease, chronic kidney disease, and chronic obstructive
pulmonary disease [35]. In this section, we discuss the role6 Journal of Biomedicine and Biotechnology
of PEDF as a possible new target molecule to therapeutically
inﬂuence cardiovascular and neurovascular diseases.
PEDF has been characterized in cardiovascular systems.
It has a protective role in atherosclerosis, the main cause of
CHD,MI, and HF,due to its anti-inﬂammatory, antioxidant,
and antithrombotic eﬀects in the vessel wall and platelets.
Expression of PEDF by ECs is essential for the inhibition of
proliferation and migration of smooth muscle cells after bal-
loon injury [82]. The antioxidative properties of PEDF have
been shown to block TNF-α-induced EC activation [83].
These observations suggest that PEDF might have beneﬁcial
eﬀects on atherosclerosis by suppressing inﬂammatory pro-
liferative responses to injury. Additionally, PEDF has strong
antiangiogenic eﬀects by inducing apoptosis [84]i nE C s
and by regulating the expression of other angiogenic factors.
Local blocking of PEDF (e.g., in ischemic tissue in the heart)
might favor angiogenesis, induce neovascularization, and
lead to increased perfusion of the injured tissue. In contrast,
local overexpression of PEDF restricted to atherosclerotic
lesions might block angiogenesis, inﬂammation, and throm-
bosis at these sites and thus counteract destabilization and
rupturing of the lesion otherwise caused by inﬂammatory
activation[85]and excessive angiogenesis, therebyinhibiting
subsequent thrombus formation [4].
In our previous study, we described a streamlined
method for the rapid isolation, growth, and ex vivo expan-
sion of late outgrowth ECs from Wharton jelly of a human
umbilical cord; we evaluated the ability of these cells
to reendothelialize and inhibit neointimal hyperplasia in
injured femoral arteries ofmice. We also examined the direct
eﬀects of EPC-conditioned medium on the migration and
proliferation of human aortic smooth muscle cells and the
role of PEDF in these eﬀects. Our results showed that EPC
transplantation led to rapid reendothelialization of denuded
arteries, which resulted in signiﬁcant inhibition of neoin-
timal thickening. This was the ﬁrst report demonstrating
that EPCs derived from an umbilical cord aid in accelerating
reendothelialization and attenuating vascular remodeling at
sites of arterial injury; these eﬀects were closely associated
with PEDF[14]. These ﬁndings have implications for a novel
PEDF-related and cell-based therapy for cardiovascular and
neurovascular diseases.
MSCs can ameliorate MI injury; however, MSCs from
older donors are less eﬃcacious than those from younger
donors. More recently, Liang et al. determined how age-
related expression of PEDF aﬀects MSC therapeutic eﬃcacy
for MI. Their data showed that PEDF expression was
increased in MSCs from old mice compared to young mice
resulting in signiﬁcantly impaired therapeutic eﬃcacy in old
MSCs, compared with that in young MSCs, for treatment of
mice subjected to MI. PEDF overexpression in young MSCs
impaired the beneﬁcial eﬀects against MI injury and induced
cellular proﬁle changes in the infarct region that was similar
to administration of old MSCs. Knocking down PEDF
expression in old MSCs improved MSC therapeutic eﬃcacy
and induced a cellular proﬁle similar to administration
of young MSCs. PEDF secreted by MSCs regulated the
proliferation and migration of cardiac ﬁbroblasts. These data
provide the ﬁrst evidence that the paracrine factor PEDF
plays a critical role in the regulatory eﬀects of MSCs against
MI injury. Furthermore, the impaired therapeutic ability
of aged MSCs is predominantly caused by increased PEDF
secretion [86]. These ﬁndings indicate PEDF as a promising
novel genetic modiﬁcation target for improving aged MSC
therapeutic eﬃcacy.
Vascular and neural tissues are delicately intertwined in
functional neurovascular units. This codependence emerges
early in developmentwith the coordinated growth and tissue
modeling of both cellular elements [87]. Stem/progenitor
cells in the developing central nervous system and in
neurogenic regions of the adult brain are stimulated to self-
renew and generate more neurons by factors released from
various vascular cells [88]. In the mammalian brain, neuro-
genesis persists in 2 germinal areas, the subventricular zone
(SVZ), and the hippocampus, where continuous postnatal
neuronal production seems to be supported by neural stem
cells (NSCs) [89]. Ram´ ırez-Castillejo et al. identiﬁed PEDF
as critical for the communication between vascular and
neural cells in an adult NSC niche, the SVZ [90]. A single
factor that can stimulate brain tumor cells to diﬀerentiate
and, at the same time, cut oﬀ their blood supply has
unlimited therapeutic value. PEDF levels decline with aging,
possibly contributing to cell senescence and to age-related
susceptibility to cancer [91]. These data demonstrate that
PEDF isa niche-derived regulator ofadult NSCsand provide
evidence for a role for PEDF in NSC maintenance.
The potential of NSCs for brain repair depends on
their capacity for self-renewal. Recent evidence for the close
apposition of adult periventricular NSCs and blood vessels
has conﬁrmed the ﬁndings [88, 90]t h a tf a c t o r sd e r i v e d
from the vasculature contribute to regulation of the adult
NSC pool [92, 93]. A new study by Andreu-Agullo et al.
revealed that the vasculature-derived PEDF promotes the
Notch signaling-dependent renewal of adult periventricular
NSCs through an unconventional mechanism [94]. They
found that Notch was active in astroglia-like NSCs butnot in
transit-amplifying progenitors of the murine subependymal
zone and that the level of Notch transcriptional activity cor-
related with self-renewal and multipotency. Moreover, divid-
ing NSCs appeared to balance renewal with commitment
via controlled segregation of Notch activity. PEDF enhanced
Notch-dependent transcription in cells with low Notch
signaling, thereby subverting the output of an asymmetrical
division to the production of 2 highly self-renewing cells.
Mechanistically, PEDF induced a noncanonical activation of
the nuclear factor (NF)-κB pathway. These data provide a
basis for stemness regulation in vascular niches and indicate
thatNotchand PEDFcooperatetoregulateself-renewal [94].
6.Conclusions
PEDF has been described as a natural angiogenesis inhibitor
with neurotrophicandimmune-modulationproperties[95].
It balances stem/progenitor cell-associated angiogenesis in
t h ee y e ,a sw e l la sc a r d i o v a s c u l a ra n dn e u r o v a s c u l a rs y s t e m s ,
and blocks tumor progression. The mechanisms underlying
most of these events are not completely clear; however, itJournal of Biomedicine and Biotechnology 7
appears that PEDF acts via multiple high aﬃnity ligands
and cell receptors. In this paper, we summarized the current
knowledge on the important endogenous antiangiogenic
molecule PEDF; we focused on the recently identiﬁed role
of PEDF as a possible new target molecule to inﬂuence
stem/progenitor cell-related neovascularization. We dis-
cussed the multimodal activities of PEDF and addressed
the therapeutic potential of PEDF in treating angiogenesis-,
neurodegeneration-, and inﬂammation-related diseases.
However, many questions remain to be resolved; these
speciﬁc points must be addressed prior to initiation of any
human clinical trials using PEDF peptides.
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